Short answer
Atrium Therapeutics, Inc. (RNA) filed its Q2 2026 10-Q quarterly report on Aug 13, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $3M with net income of −$20M.
Q2 2026 key financials · XBRL
- Revenue
- $3M
- −84.7% QoQ
- Net income
- −$20M
- −21.4% QoQ
- Operating margin
- -752.9%
- EPS (diluted)
- −$1.18
- −21.6% QoQ
Source: XBRL data from the Atrium Therapeutics, Inc. (RNA) Q2 2026 10-Q on SEC EDGAR. USD.
Atrium Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly added risk: separation from Avidity increased costs, with standalone vendor charges potentially exceeding historical allocations
- Most materially updated risk: capital needs heightened after separation, with $72.3 million cash and $191.6 million short-term investments funding at least 12 months
- Regulatory risk: all programs remain discovery, preclinical, or clinical stage without completed pivotal trials or BLA submissions
- Operational risk: RNA delivery platform remains unproven for cardiac targets despite favorable neuromuscular results
- Financial risk: six-month net losses increased to $36.8 million from $20.3 million
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Atrium Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.